Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Original publication

DOI

10.1016/s1470-2045(12)70220-6

Type

Journal article

Journal

Lancet Oncol

Publication Date

06/2012

Volume

13

Pages

573 - 574

Keywords

Aged, Androgen Antagonists, Antineoplastic Agents, Hormonal, Antineoplastic Combined Chemotherapy Protocols, Disease-Free Survival, Docetaxel, Drug Resistance, Neoplasm, Evidence-Based Medicine, Humans, Male, Middle Aged, Neoplasm Invasiveness, Neoplasm Staging, Practice Guidelines as Topic, Prognosis, Prostatic Neoplasms, Remission Induction, Survival Analysis, Taxoids, Treatment Outcome, United Kingdom